Aspirin/Caffeine/Codeine Phosphate/Butalbital

精彩内容感冒、咳嗽等是日常生活中的常见病，米内网最新数据显示，2022年中国重点省市公立医院终端咳嗽和感冒化药市场继续回温，同比增长4%。从用药剂型看，注射剂“节节败退”，吸入剂、溶液剂成主流；集采品种“跌跌不休”，TOP20产品大洗牌，4大品牌销售大涨，石四药暴涨665%；20亿吸入剂备战第九批集采，人福、倍特、科伦......106个新品冲刺。市场持续回温！注射剂“节节败退”，云南药企亮眼感冒是日常生活较为常见的呼吸道疾病，通常会引发咳嗽、鼻塞、流鼻涕等症状。2022年末新冠疫情防控政策优化调整后，感冒药、退烧药、止咳药、祛痰药等用药需求激增，多地出现缺货、断货等现象。米内网最新数据显示，2020年受疫情影响，医院诊疗人数减少，中国重点省市公立医院终端咳嗽和感冒化药销售额出现较大程度下滑，2021年市场开始回温，2022年继续以4.2%的增速增长。近年来重点省市公立医院终端咳嗽和感冒化药销售情况（单位：万元）来源：米内网重点省市公立医院药品终端竞争格局从细分小类看，祛痰药（不包括含止咳药的复方制剂）占主导地位，市场份额超过70%；复方制剂近年来增长较快，感冒复方制剂、止咳药与祛痰药的复方制剂的市场份额分别由2020年的7.66%、4.88%上升至2022年的11.99%、9.12%。2022年重点省市公立医院终端咳嗽和感冒化药小类分布情况来源：米内网重点省市公立医院药品终端竞争格局从用药剂型看，随着越来越多的新品上市销售，叠加用药方便性及依存性，吸入剂、溶液剂逐渐成为咳嗽和感冒化药的主流剂型，而注射剂则“节节败退”，销售占比由2016年的57.38%持续下滑至2022年的18.25%。2022年重点省市公立医院终端咳嗽和感冒化药剂型分布情况来源：米内网重点省市公立医院药品终端竞争格局从TOP20厂家看，赞邦、北京远大九和药业、海南斯达制药位列前三，此外，云南龙海天然植物药业暴涨326.18%，表现亮眼，石家庄四药、湖北凤凰白云山药业等企业也有超50%的增长。TOP20大洗牌！4大品牌首上榜，石四药暴涨665%受疫情及国家集采影响，2022年重点省市公立医院终端咳嗽和感冒化药TOP20产品洗牌。与2021年的排位相比，吸入用乙酰半胱氨酸溶液稳居首位，注射用盐酸氨溴索被“踢出”TOP20，盐酸溴己新注射液、吸入用盐酸氨溴索溶液、乙酰半胱氨酸泡腾片、复方氨酚美沙糖浆等排位上升明显。已纳入国家集采的咳嗽和感冒化药及中标情况来源：米内网一致性评价进度数据库福多司坦口服常释剂型被纳入第二批集采，于2020年4月陆续落地执行，2020年在重点省市公立医院终端销售额暴跌接近70%，之后“跌跌不休”。在咳嗽和感冒化药TOP20产品中，福多司坦片由2019年的第6位下滑至2020年的第12位，2021年被挤出TOP20。近年来重点省市公立医院终端福多司坦口服常释剂型销售情况（单位：万元）来源：米内网重点省市公立医院药品终端竞争格局氨溴索注射剂被纳入第四批集采，于2021年5月陆续落地执行，2021年在重点省市公立医院终端销售额大跌超过50%。在咳嗽和感冒化药TOP20产品中，注射用盐酸氨溴索由2020年的第4位下滑至2021年的第9位，2022年被挤出TOP20；盐酸氨溴索注射液则由2019年的首位下滑至2022年的第3位。近年来重点省市公立医院终端氨溴索注射剂销售情况（单位：万元）来源：米内网重点省市公立医院药品终端竞争格局2022年重点省市公立医院终端咳嗽和感冒化药TOP20品牌中，11个品牌大涨超10%，其中云南龙海天然植物药业的盐酸氨溴索注射液、石家庄四药的盐酸溴己新注射液、韩美的吸入用盐酸氨溴索溶液、湖北凤凰白云山药业的复方氢溴酸右美沙芬糖浆涨超50%。2022年重点省市公立医院终端咳嗽和感冒化药TOP20品牌来源：米内网重点省市公立医院药品终端竞争格局从品牌排名变化看，石家庄四药的盐酸溴己新注射液（+665%）、韩美的吸入用盐酸氨溴索溶液（+82%）、河北国金药业的小儿氨酚黄那敏颗粒（+6%）、湖北凤凰白云山药业的复方氢溴酸右美沙芬糖浆（+54%）首次上榜；云南龙海天然植物药业的盐酸氨溴索注射液（+326%）集采中选后放量，排位大幅上升，勃林格殷格翰的盐酸氨溴索注射液（-75%）集采未中选，排位大幅下滑。倍特、科伦......106个新品在路上，人福首仿来袭咳嗽和感冒化药过评情况来源：米内网中国申报进度（MED）数据库米内网数据显示，目前21个咳嗽和感冒化药已有企业过评或视同过评，从企业过评情况看，河北仁合益康、一品红制药、康恩贝、扬子江药业、天津医药、北京诚济制药、福安药业、江西亿友药业、美大康药业、万邦德制药等企业均有3个及以上的品种过评。盐酸氨溴索注射液、盐酸氨溴索口服溶液、盐酸氨溴索片、氨溴特罗口服溶液、盐酸溴己新注射液、乙酰半胱氨酸雾化吸入溶液6个品种过评企业数均达6家及以上，其中盐酸氨溴索口服溶液、氨溴特罗口服溶液、乙酰半胱氨酸雾化吸入溶液暂未纳入国家集采，有望纳入第九批集采。乙酰半胱氨酸吸入剂2021年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售额超过20亿元，目前已有福安药业庆余堂、康缘药业、朗科生物、健康元、仁合益康、普洛药业6家企业过评。新分类申报且在审的咳嗽和感冒化药来源：米内网中国申报进度（MED）数据库除了已获批产品，目前还有15个咳嗽和感冒化药有企业以新分类申报且在审，涉及106个品种（以药品名+企业计），其中氨酚咖妥胶囊、吸入用盐酸溴己新溶液暂无首仿（含剂型首仿）获批。吸入用盐酸溴己新溶液新分类申报情况来源：米内网中国申报进度（MED）数据库目前有6家药企以新分类提交吸入用盐酸溴己新溶液上市/临床申请，且均已获批临床，其中海南葫芦娃药业、江西亿友药业、江西东抚制药/江西新先锋医药、上海禾丰制药等企业的产品已步入III期临床。氨酚咖妥胶囊临床试验进展来源：米内网中国临床试验数据库氨酚咖妥胶囊目前国内市场空白，仅人福独家以新分类申报临床，目前已完成与参比制剂氨酚咖妥胶囊（商品名：Fioricet）的生物等效性试验。资料来源：米内网数据库注：米内网重点省市公立医院化学药终端竞争格局数据库是以20+省市，近700家样本省市公立医院的化学药采购数据为基础，对化学药全品类进行连续监测的样本省市样本医院数据库。数据统计截至4月12日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

Healthcare information technology has opened new doors to understanding opioid addiction, but there still are areas where data and innovation can help medical professionals better handle this crisis, contends Reema Hammoud, PharmD, assistant vice president of clinical pharmacy at Sedgwick, a vendor of technology-enabled risk, benefits and integrated business systems. The COVID-19 pandemic is a major health crisis that has taken center stage, but the still-rising opioid crisis is a large-scale epidemic that cannot be overlooked. It is a crisis in desperate need of innovative solutions, and certainly technology can be one sector that provides them. Healthcare IT News interviewed Hammoud to discuss the opioid crisis and IT, specifically, metrics to track potential abuse and abuse mitigation strategies providers can pursue, and the best ways to proceed and how health IT can help when there is no one-size-fits-all approach for pain management or addressing substance use disorder. Q. You say there are metrics healthcare professionals can use to track potential abuse. What are they, where can they be obtained and what role can health IT play here? A. It's no surprise that drug abuse in the U.S. has skyrocketed in recent years. In fact, the CDC recently released a report that found overdoses involving fentanyl and other synthetic opioids surpassed 71,000, which is up 23% from the previous year, as well as a 23% increase in deaths involving cocaine and a 34% increase in deaths involving methamphetamines and other stimulants. Additionally, according to a 2021 Quest Diagnostics study , the use of amphetamines, including prescription medications such as Adderall, has more than doubled in the past 10 years. Further, more than 50% of respondents reported using a prescription stimulant when not prescribed for them, according to a recent study from The American Professional Society of ADHD and Related Disorders. These statistics mainly account for prescription drugs only, but many of these medications can be very dangerous when mixed with other substances, including alcohol and cannabis. As drugs continue to circulate the streets, there are several means for healthcare professionals to track abuse and safely provide help to patients. The first and most important is understanding your patient's health and history of prescription and recreational drugs. Electronic medical records, coupled with a detailed verbal history from patients, have helped healthcare professionals better analyze medical records and make more informed decisions when prescribing medication. These records will detail what medication a patient is receiving, where they are getting it from, how often they fill it, and so on. While looking at these records, random drug testing also can help paint a clear picture to monitor for potential drug abuse. This allows prescribers to look at medications from both a qualitative and quantitative perspective. For example, if a patient says they are taking two oxycodone pills during the day, but they only took it once and used cannabis instead, prescribers will be able to track potential abuse and alter prescription medications swiftly and accordingly. Another very helpful tool is Prescription Drug Monitoring Programs (PDMPs), which assist physicians and pharmacists when they are prescribing and dispensing scheduled medicines. These electronic records, which are available in most states, track and flag controlled substance prescriptions. For example, if a patient received oxycodone from a pain specialist and alprazolam from a psychiatrist, the PDMP would alert the prescriber to discuss medication usage with patients to gauge whether they are using these controlled substances in a safe way. Additionally, states typically share data with one another so individuals who live close to another state cannot double up on prescriptions or take potentially harmful combinations of drugs without the counsel of a professional. While these tracking systems are incredibly helpful, a large problem is that many physicians and pharmacists do not fully use them. Should these technologies be widely adopted and implemented, medical professionals have a better chance of tracking potential abuses. Q. There are abuse-mitigation strategies healthcare providers can pursue. What are some of them, and how can health IT support them? A. Counseling needs to be top of mind for healthcare professionals. Discussing drug side effects, potential abuse factors, bad interactions and other dangers is a critical mitigation strategy and ultimately can impact patient safety. This should be the case for all situations whether prescribing a medication for the first time or an individual is actively using a drug or in recovery. Another mitigation strategy is pill counting, though it is time-consuming. For example, if a patient was prescribed Oxycontin two weeks ago and the doctor asks them to bring in the bottle, there should be 15 pills left for a 30-day fill. If there are fewer, it's likely the patient is either abusing the drug or selling it. Because this manual process often can be tedious, technology helps expedite the numbers. This was recently seen where a patient was prescribed 150 tablets of Oxycontin for a 30-day supply; however, the patient kept filling the prescription 10-15 days early every month. This patient's behavior was identified through PDMP, and utilization trends were identified through electronic medical records. In less than 18 months, the patient received 1,237 extra tablets of Oxycontin, and there was no clear explanation on how those extra tablets were utilized. Situations like this one are often very dangerous without technology and proper monitoring. Drug Utilization Reviews [DURs] at pharmacies also are very helpful when mitigating drug abuse. These programs alert pharmacists if a patient is getting medications that are dangerous when combined. This feature oftentimes is used to identify drug abuse or risk, but due to the chaotic nature of retail business, pharmacists often override these warnings. Whether pharmacies are chain, family owned, private or public, all DUR programs are processed through insurance, reducing the risk of individuals filling multiple prescriptions within a dangerous time frame. When combined with drug screenings, a patient's entire prescription history can be on hand for prescribers, detailing possible combinations that could lead to devastating circumstances. Q. You suggest there is no one-size-fits-all approach for pain management or addressing substance use disorder. What's the best way for providers to proceed, and how can health IT support them in this process? A. Individualizing patient care and involving them in decision-making not only ensures better treatment, but yields successful outcomes. Understanding a patient's approach to their health, knowing their personal medications, prescription and over-the counter, and any workers' compensation medications could provide a good baseline status. For example, if someone is receiving Norco under a workers' compensation program but also prescribed Fioricet for headaches by a primary care physician and taking Tylenol PM over the counter, the patient might think of them as different medications, but in reality, they all have a common ingredient, acetaminophen. This combination can be very dangerous and could lead to unintentional overdose. It's also critical to understand the medicine when prescribing it to a patient as some drugs at a certain dose might not be recommended for female patients over the age of 65. Therefore, individualizing medication doses based on their demographics is important. To curb the opioid epidemic, to help patients successfully wean off the opioids, and cope with pain, individualizing care is crucial. It's never recommended to abruptly discontinue medication, but it's the onus of the medical professionals to safely wean patients off. There is data throughout the healthcare industry to help better understand doses, and incorporating personalized care, alongside counseling, can help former abusers avoid falling into old habits.